Download Free Medical Clinical Case For Ions PowerPoint Presentation

Clinical Case For Ions PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Clinical case for ions” by Reinhard Schulte, MD,MS, DABR.

This medical PowerPoint presentation is about ion therapy, also known as particle therapy or proton therapy. Ion therapy is a type of cancer treatment that uses high-energy charged particles, such as protons or carbon ions, to kill cancer cells. Ion therapy works by targeting cancer cells with a beam of ionizing radiation that damages the DNA in the cancer cells, causing them to die.

One of the benefits of ion therapy is its ability to deliver high doses of radiation to the tumor while minimizing damage to surrounding healthy tissues. This is because the ion beam can be precisely targeted to the tumor, minimizing exposure to nearby normal tissues. Ion therapy is particularly useful for treating tumors in sensitive areas of the body, such as the brain, where minimizing damage to surrounding tissues is critical.

Ion therapy is a relatively new technology and is not widely available. It requires specialized equipment and expertise, which makes it more expensive than other forms of radiation therapy. However, studies have shown that ion therapy can be very effective for certain types of cancer, particularly when used in combination with other treatments such as chemotherapy or surgery.

Tags : ion therapy, particle therapy, proton therapy, cancer treatment, cancer cells, Nuclear Medicine, Nuclear Medicine PowerPoint presentation

Published on : Jun 20, 2023 | Views : 1142 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Clinical case for ions Reinhard Schulte, MD,MS, DABR Professor, Radiation Research Loma Linda University Principal Investigator Particle Therapy Research Grant (P20) UCSF Helen Diller Family Comprehensive Cancer Center In his last State of the Union Address to the nation, President Obama announced a national initiative to find a cure for cancer, an ambitious "moon shot" that Vice President Joe Biden will direct in the remaining months of the administration Apollo 11 lunar landing, Courtesy NASA
Slide 2-

Does Ion Therapy Need a Moon Shot Approach? There are some parallels with the ambitious competition to land a man on moon and to cure cancers with ion therapy Like the moon landing, a large technological effort may be needed to make it happen Saturn V SC Carbon Gantry at HIMAC 2
Slide 3-

Terminology Radiation therapy may be categorized into External beam therapy Brachytherapy Radioimmunotherapy (RIT) External radiation therapy can be further divided into Photon therapy (Co-60, linacs) Electron therapy (linacs) Fast neutron therapy (cyclotrons) Charged particle therapy (proton and ion therapy with particle accelerators) This talk will primarily focus on ion therapy with helium or carbon ions, and possibly other ions 3
Slide 4-

Outline Radiation therapy in the 21st century – is there a case for ions? What distinguishes ions from protons and photons? (physics and biology) Clinical experience with carbon Ions – Are we on the right track? New initiatives in the development ion therapy in the U.S. Summary & Outlook 4
Slide 5-

Radiation therapy in the 21st century – is there a Case for ions? 5
Slide 6-

Modern Radiation Therapy – Any Role for Protons and Ions? Radiation therapy has seen a dramatic development in the last 30 years New delivery technologies (VMAT, Cyberknife, IMRT, proton therapy) Improved imaging technology (PET, MRI, 4D CT, imaging guidance) New fractionation schemes (SBRT, hypofractionation, SRS) New combination therapies chemo-radiation molecularly targeted therapeutics Improved follow-up and patient survivorship care Is there any role for ions? 6
Slide 7-

Cancer survival and mortality – where to we stand? "The five-year survival rate for all cancers improved from 51% in the early 1980s to almost 60% in the early 1990s ..., since the 1971 National Cancer Act, much of the research into early cancer has paid off" (Press release of the US Dept. of Health and Human Services, 2000) However, a SEER-data-based analysis by Welch et al (JAMA, 2000) found that Between 1950 and 1995, 5-year survival increased by more than 25% in only 6 out of 20 most common cancers and by less than 10% in another 6 out of 20 cancer types, with remaining 8 cancers types increasing between 10% and 20% Increase in 5-year survival was typically related to increase in incidence and earlier detection (prostate cancer) Mortality rates of most common cancers are increasing or flat 7
Slide 8-

The successful cancers 8
Slide 9-

The unsuccessful cancers 9
Slide 10-

Advancements in Radiation Therapy and their Impact We have seen many exciting incremental technological advancements in RT as a local-regional treatment modality, including 3D Conformal radiotherapy (3DCRT) Intensity modulated radiation therapy (IMRT) Stereotactic body radiation therapy (SBRT) Image-guided radiotherapy (IGRT) For some sites, this has also led to an improvement in long-term survival For many sites, it has also lead to a reduction of side effects and an improvement in quality of life 10
Slide 11-

Local-Regional Control Improves Breast Cancer Survival Breast cancer is one of few sites where a survival advantage due to better local-regional control with RT has been demonstrated in large meta-analyses, this is on top of additional improvement in control and survival from chemotherapy, hormone therapy, and targeted therapy (HER2-directed) The statistically proven survival advantages do not show earlier than 10-15 years and require large patient numbers These results contrast earlier studies that showed that addition of RT to surgery in breast cancer patients reduces overall survival, most likely due to increased cardiac toxicity with outdated radiation techniques 11
Slide 12-

Improved Local-Regional Control after RT Improves Breast Cancer Survival The Oxford review analysis (Lancet. 2011, 378(9804), 1707–1716) showing the impact of radiation therapy on breast cancer local recurrence, mortality and death from all causes. Overall, about one breast cancer death was avoided by year 15 for every four recurrences avoided by year 10. 12
Slide 13-

Improved Local-Regional Control after RT Improves Breast Cancer Survival especially in patients at higher risk for LR In women with pN0 disease on average one death from breast cancer is avoided for every four recurrences avoided There is a trend of larger avoidance of death in women with larger risk of local-regional recurrence Absolute reduction in 15-year risk of breast cancer death RT after breast-conserving surgery versus absolute reduction in 10-year risk of any recurrence (Lancet 2011) 13
Slide 14-

Improved Outcome in RT comes at the Cost of Higher Cardiac Toxicity RCTs conducted over the last 30 years demonstrated beneficial local control and survival after BCT/mastectomy RT. With dose-sparing modern approaches, the absolute benefits of radiation may be increased 14 Relative risk (RR) of cardiac death after RT for left versus right breast cancer (laterality) Bird, Swain Clin Cancer Res. 2008;14(1):14-24.
Slide 15-

Risk of ischemic heart disease in women after RT for breast cancer – Can protons reduce it? A population-based case control study by Darby et al. demonstrated that the risk of MCEs increased progressively with the cardiac radiation dose, by 7.4 percent for each 1 Gy of radiation to the heart This initiated a first randomized U.S. trial to compare the cardiac late effects of proton therapy with those of photon therapy for breast cancer funded by PCORI 15 Rate of increase of major coronary events vs. mean RT dose to the Heart, as Compared with the estimated rate with no radiation exposure to the heart. (Darby et al., N Engl J Med. 2013;368(11):987-98
Slide 16-

Cure of Advanced Cancer – An Elusive Dream? There are still many advanced tumors which are diagnosed late and that even if they are still local or regional cannot be cured with RT nor with any other therapy Possible reasons (pointing to ion therapy) include Advanced tumors have a higher fraction of hypoxic and aggressive stem cells that are geared towards survival, they tend to be resistant RT, invasive, & drive further mutations (tumor heterogeneity) Advanced tumors are generally larger and contain more stem cells that need to be eliminated Advanced tumors have a larger propensity for local infiltration and regional and distant spread 16
Slide 17-

Potential reasons why higher doses of low-LET may be ineffective in advanced cancers Advanced tumors including lung, esophageal, and malignant brain tumors (GBMs) have shown no further increase in local & regional control with dose escalation Potential reasons (pointing to the use of ions) could be Increased toxicity in normal tissues surrounding the tumor (e.g., central location of lung tumors) Circulating tumor cells (CTCs) attack and overwhelm the immune system – cancer initiated immune suppression (all tumors shedding CTCs) We may not know the true target harboring the most aggressive part of the tumors (GBMs) 17
Slide 18-

What distinguishes ions from protons and photons? (physics and biology) 18
Slide 19-

Physics of Photons, Protons, Ions Charged particles comprised of protons or heavier ions share the Bragg peak characteristic, which makes them dose-volume sparing RT modalities Heavier ions have a larger peak to plateau ratio Heavier ions have a sharper lateral dose fall-off (penumbra) Heavier ions have a distal fragmentation (dose) tail 19
Slide 20-

Radiobiological Characteristics Protons and heavier ions have excellent dose-localization properties Ions produce a much denser track structure (primary ionizations and secondary electrons) The closely spaced ionizations lead to a larger number of complex and clustered DSBs, which are difficult to repair and less sensitive to the presence of absence of oxygen W.T. Chu, Proc. of 10th heavy ion charged particle therapy symposium, 2011. 20
Slide 21-

Clinical Experience with Carbon Ions – Are we on the right track? 21
Slide 22-

Exploiting the improved dose-localization & higher BE of ions 22
Slide 23-

Clinical experience at NIRS The HIMAC facility of NIRS in Tokyo, Japan has accumulated the largest clinical experience with carbon ions since 1994 (2 years after the LBNL program ended) Experience was gathered with well-planned Phase I/II dose escalation and subsequent prospective follow-up of patients in several different tumor sites, including Bone and Soft-tissue Tumors Lung Cancer (early and advanced) Locally Recurrent Rectal Cancer Prostate Cancer (early and advanced) Skull Base and Head-and-Neck Tumors Hepatocellular Carcinoma Locally Advanced Cervical Cancer Pancreatic Cancer 23
Slide 24-

Clinical Experience with Bone and Soft Tissue Sarcomas at NIRS A clinical trial for these rare tumors started in June of 1996 By 2010 more than 700 patients had been treated, increasing at an annual rate of 100-150 patients Sacral chordomas, which have a high surgical morbidity and many presenting with a huge sacral mass, sacral chordomas accounted for the largest proportion (>100 patients) Local control was achieved in about 80% of patients, comparable to excessive surgery Ninety percent of the patients retained the ability to walk on their own 24
Slide 25-

Clinical Experience with Lung Tumors at NIRS CIRT was first used for lung cancer in November of 1999, and a total of 918 were treated during the first 11 years. For the initial treatment, a dose escalation study of 18 fractions over 6 weeks was performed for peripheral stage I lung cancer, central lung cancer, and lung cancer that had invaded the chest wall (as preoperative irradiation) For peripheral type stage I non-small-cell lung cancer, there was subsequent reduction in the fractions from 9 fractions (3 weeks) to 4 fractions (1 week) Comparing to surgery and SBRT, it appears that local control and survival rates are similar 25
Slide 26-

Clinical Experience with Prostate Cancer at NIRS A clinical trial started in June 1995 and 1202 cases of prostate cancer had been treated by July 2010 Ninety-six (96) cases were treated in early dose escalation trials, 175 cases in a phase II clinical trial, 909 cases thereafter In 2007 the therapy scheme was shortened from 20 times in 5 weeks to 16 times in 4 weeks Eligible patients had locally confined and path- confirmed prostate cancer case; they were classified into 3 groups (high risk, intermediate risk and low risk) according to the clinical stage, initial PSA value, and pathological Gleason score Considering >50 % of the cases were high risk, the 5-year overall survival rate of ~95％, relapse-free rate of more than 90％ appears satisfactory Rectal and urinary toxicity appears lower that with IMRT and protons 26
Slide 27-

Clinical Experience with Hepatocellular Carcinoma at NIRS HCC is an increasingly common tumors mostly caused by chronic infection with Hepatitis virus B or C and liver cirrhosis A series of 4 dose escalation studies of carbon ion radiotherapy for the treatment of HCC as an alternative to surgery or transarterial chemo-embolization were conducted between June 1995 and August 2005 to determine the optimal dose when given in 15 fractions over five weeks. Eventually, the treatment schedule was simplified from 15 fractions over five weeks to two fractions for two days. The majority of patients had relapsed after or were refractory to other therapies, ore were judged as non-responsive to conventional therapies The 1-, 3-, and 5-year local control rates were in the range of 89%–98%, 81%–95%, and 81%–95%, respectively. A shorter duration tended to yield a higher local Hepatic toxicity was mild for most patients. The proportions of patients whose Child-Pugh score increased from baseline by two or more points due to late tended to be smaller with a smaller number of fractions. 27
Slide 28-

Clinical Experience with Pancreatic Cancer at NIRS Pancreatic cancer is the fifth leading cause of cancer death in Japan and is considered to be one of the most lethal cancers. An initial phase I/II dose escalation clinical trial for pre-operative CIRT with 16 fractions in 4 weeks for resectable pancreatic was started in 2000 Subsequent clinical trials aimed at shortening the fraction size to 8 fractions in 2 weeks and treating patients with locally advanced pancreatic cancer followed by an ongoing clinical trial of CIRT combined with anticancer drug gemcitabine starting in 2005 Twenty-three (23) patients underwent preoperative CIRT between April 2003 through February 2010. Nineteen (19) patients had curative resection (resection rate 83%), while the remaining 4 patients did not undergo surgery due to liver metastases or because surgery was refused. In the 19 surgical cases, the 3-year local control rates and overall survival rates were 100% and 40%, respectively. Thirty-eight (38) patients underwent primary chemo-CIRT between April 2007 and February 2010. Local control by increased along with CIRT dose escalation. In the high dose group, in which patients were irradiated with at least 45GyE, local recurrence developed in only one out of the 14 patients. The one year local control rate was 86%. The median survival was 18 months, and the 1-year and 2-year overall survival rates were 66% and 34%, respectively Updated results show further improvement of 3-year overall survival rates now approaching 50% 28
Slide 29-

Summary of Clinical Experience with Carbon Ions Clinical experience with ion therapy accumulated at HIMAC and now at several other centers in Europe and Asia, is promising in terms of local control, overall survival, and lack of severe side effects However, there is not level I evidence from randomized clinical trials involving or comparing ion therapy The bulk of the NIRS experience seems to points toward better result with shorter fractionation schedules (hypofractionation) A randomized comparison with IMRT/SBRT for the tumors sites selected at NIRS seems warranted 29
Slide 30-

New initiatives in the development ion therapy in the U.S. 30
Slide 31-

More than 60 participants from medicine, physics, biology & business were charged with addressing 4 topics: Charge 1: Identify pertinent clinical applications and radiobiological requirements Charge 2: Assess corresponding beam requirements for future treatment facilities Charge 3: Assess the corresponding beam delivery system requirements Charge 4: Identify R&D activities needed to bridge the gap DOE-NCI Workshop on Ion Beam Therapy, Bethesda, MD, January 2013 31
Slide 32-

P20 Announcement Feb & Nov 2013 32
Slide 33-

UCSF – P20 Application 2014 – Review Summary Statement 33
Slide 34-

UCSF- NAPTA P20 Grant –Specific Aims Administrative Core Specific Aim 1: Create Functional Teams Specific Aim 2: Create Organizational Structure Specific Aim 3: Perform Pilot Research (enhance infrastructure Pilot Research Specific Aim 1: Demonstrate practicability of IGAPRT with pCT Specific Aim 2: Advance radiobiological modeling Specific Aim 3: Develop IGAPRT using the results of 1 and 2 34
Slide 35-

A New Ion RT Radiobiology? The traditional line of investigating the benefits of ion beam therapy has been to treat radioresistant cancers with ions. New research should focus on interaction of high LET and hypofractionation with the immune system and targeting innate immunosuppressive mechanisms The body of work suggests that RT generates a trigger of the innate immune system to activate tumor-specific T cells overcoming some of the barriers to tumor rejection For 2016, we are planning to launch a collaborative research program addressing the compelling question whether high LET ions have an advantage in this respect 35
Slide 36-

FDG-PET Scans of lung cancer patient treated with ipilimumab and RT for a single intrahepatic metastasis Golden & Formenti Oncoimmunology 2014 36
Slide 37-

Clinical Implications of the “New Radiobiology” A differential immune response to high LET ions (such as carbon) may have a much broader application for the treatment of cancer patients Ions may then be of value in treating patients with common cancers suffering from systemic disease. This broader application would make the use of ions far more cost-effective because: far fewer fractions would be required the technical requirements would be less challenging The nature of future clinical ion trials would be modified: systemic disease survival endpoints will be reached earlier and more patients will be available. 37
Slide 38-

Summary & Outlook Ion therapy has come a long way, and warrants further investigation Major promises include better dose localization (already with helium) and higher biological effectiveness A new radiobiology should be further explored, leading to a reduction of the metastatic incidence or burden in particular with hypofractionated high LET radiation Additional technology development is required to close the gap to advanced photon therapy techniques Major efforts should be directed toward more compact and less expensive technology 38
Slide 39-

Thank you! 39